ipd_sharing: Yes

status: Recruiting

title: A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

lead_sponsor: Merck Sharp & Dohme LLC

type: Registry Identifier

location_country:
Spain
Italy
United Kingdom
Lithuania
Ukraine
United States
Belgium
Japan
Philippines
Romania
South Africa
Czechia
Poland
Hong Kong
Portugal
Austria
Australia
Russian Federation
Argentina
Puerto Rico
Israel
Turkey
Mexico
Norway
Malaysia
Singapore
Sweden
Brazil
Canada
Switzerland
Guatemala
Hungary
China
Germany
Denmark
Taiwan
Greece
Ireland
Estonia
Latvia
Finland
New Zealand
Thailand
Korea, Republic of
France
Chile
Colombia
Netherlands

location_facility: Tasman Oncology Research Pty Ltd ( Site 3012)

location_facility: University of Virginia Health System ( Site 0035)

location_facility: James Graham Brown Cancer Center ( Site 0058)

location_facility: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032)

location_facility: Lung Center of the Philippines ( Site 1705)

location_facility: National Taiwan University Hospital ( Site 3200)

location_facility: Instytut Centrum Zdrowia Matki Polki-Klinika Onkologii ( Site 1609)

location_facility: Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0

location_facility: Sotiria Regional Chest Diseases Hospital of Athens ( Site 1850)

location_facility: West Cancer Center and Research Institute ( Site 0055)

location_facility: N.N.Petrov Research Institute of Oncology-Department of Preclinical and Clinical Research ( Site 121

location_facility: Seattle Cancer Care Alliance ( Site 0024)

location_facility: Okayama University Hospital ( Site 3107)

location_facility: Hospital Universitario Quiron Madrid ( Site 0868)

location_facility: Hospital Clinico de Valencia ( Site 0858)

location_facility: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056)

location_facility: St.Luke's International Hospital ( Site 3120)

location_facility: Private Enterprise Private Manufacturing Company Acinus-Medical and Diagnostic Centre ( Site 3656)

location_facility: Centro Hospitalar Lisboa Norte E.P.E. - Hospital Pulido Valente ( Site 1750)

location_facility: Universitaetsklinikum des Saarlandes ( Site 2411)

location_facility: Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII-UOC Oncologia ( Site 1967)

location_facility: Centre Hospitalier de l Universite de Montreal - CHUM ( Site 2807)

location_facility: Faculty of Medicine Siriraj Hospital ( Site 2365)

location_facility: The First Affiliated Hospital, Sun Yat-sen University-pneumology department ( Site 3459)

location_facility: Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1010)

location_facility: Guangdong Provincial People's Hospital-Cancer Center ( Site 3462)

location_facility: Comprehensive Cancer Centers of Nevada ( Site 0043)

location_facility: UZ Leuven - Campus Gasthuisberg ( Site 2906)

location_facility: National Hospital Organization Himeji Medical Center ( Site 3111)

location_facility: Chang Gung Medical Foundation-Linkou Branch ( Site 3206)

location_facility: St John of God Subiaco Hospital ( Site 3013)

location_facility: St James University Hospital ( Site 0509)

location_facility: Leningrad Regional Oncology Dispensary-Outpatient chemotherapy department ( Site 1218)

location_facility: C.H.U. de Tours - Hopital Bretonneau ( Site 2515)

location_facility: I.E.U. Medical Point Hastanesi-Oncology ( Site 1310)

location_facility: CHRU Lille Hospital Claude Huriez ( Site 2506)

location_facility: Hospital Clinico San Carlos ( Site 0857)

location_facility: Hospital Universitario Virgen de la Victoria ( Site 0878)

location_facility: Hospital de Clinicas de Porto Alegre ( Site 1000)

location_facility: A. C. Camargo Cancer Center ( Site 1002)

location_facility: CHU de Brest -Site Hopital Morvan ( Site 2504)

location_facility: UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009)

location_facility: University Malaya Medical Centre ( Site 0626)

location_facility: Dana-Farber Cancer Institute ( Site 0006)

location_facility: Austin Health-Austin Hospital ( Site 3004)

location_facility: Melanoma Institute Australia ( Site 3001)

location_facility: Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 1972)

location_facility: Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1968)

location_facility: UPR Comprehensive Cancer Center ( Site 1150)

location_facility: Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054)

location_facility: National Cancer Institute-Chemotherapy departament with day care unit ( Site 3301)

location_facility: Békés Megyei Központi Kórház Pándy Kálmán Tagkórház-Megyei Onkológiai Centrum ( Site 1405)

location_facility: Acibadem Adana Hospital-Pediatric Hematology-Oncology ( Site 1312)

location_facility: Memorial Sloan Kettering Cancer Center ( Site 0012)

location_facility: Medizinische Hochschule Hannover ( Site 2402)

location_facility: Tokyo Metropolitan Komagome Hospital ( Site 3133)

location_facility: Hospital Universitario La Paz ( Site 0853)

location_facility: Texas Oncology-Baylor Sammons Cancer Center ( Site 0062)

location_facility: Seoul National University Bundang Hospital ( Site 0951)

location_facility: CHA Bundang Medical Center CHA University ( Site 0957)

location_facility: Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 2522)

location_facility: Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0851)

location_facility: West China Hospital Sichuan University-respiratory ( Site 3473)

location_facility: Municipal institution of Lviv regional council Lviv Oncology-Chemotherapy ( Site 3653)

location_facility: Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0871)

location_facility: Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 2751)

location_facility: Universitair Medisch Centrum Groningen ( Site 1550)

location_facility: Universitaetsklinik Muenchen ( Site 2406)

location_facility: Hadassah Ein Kerem Medical Center ( Site 2051)

location_facility: UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004)

location_facility: Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site

location_facility: Seoul National University Hospital ( Site 0953)

location_facility: Japanese Foundation for Cancer Research ( Site 3146)

location_facility: Ankara City Hospital-Medical Oncology ( Site 1311)

location_facility: Radboud University Medical Center ( Site 1554)

location_facility: Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council ( Site 3650)

location_facility: Instituto de Oncologia de Rosario ( Site 1350)

location_facility: Hospital Universitario Gregorio Maranon ( Site 0864)

location_facility: Northern Jiangsu People's Hospital-General Surgery Department ( Site 3474)

location_facility: Princess Margaret Cancer Centre ( Site 2803)

location_facility: Tokyo Medical and Dental University Hospital ( Site 3149)

location_facility: Transcarpathian Regional Clinical Oncology Center-Chemotherapy dept. ( Site 3652)

location_facility: Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016)

location_facility: Centre Hopitalar Leon-Berard ( Site 2519)

location_facility: Fudan University Shanghai Cancer Center ( Site 3467)

location_facility: Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 0702)

location_facility: Antoni van Leeuwenhoek Ziekenhuis ( Site 1551)

location_facility: Royal Brisbane and Women s Hospital ( Site 3009)

location_facility: Wakayama Medical University Hospital ( Site 3124)

location_facility: Universitaetsspital Zuerich ( Site 0750)

location_facility: St. Luke's University Health Network ( Site 0017)

location_facility: Nottingham University Hospitals NHS Trust ( Site 0510)

location_facility: Medizinische Universität Wien ( Site 2953)

location_facility: Saitama Medical University International Medical Center ( Site 3118)

location_facility: The Angeles Clinic and Research Institute ( Site 0005)

location_facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1612)

location_facility: California Cancer Associates for Research & Excellence ( Site 0016)

location_facility: Ege Universitesi Tip Fakultesi Hastanesi ( Site 1300)

location_facility: Osaka International Cancer Institute-Gynecologic Oncology ( Site 3129)

location_facility: Hospital Clinico Universitario Lozano Blesa ( Site 0859)

location_facility: Hacettepe Universitesi-oncology hospital ( Site 1304)

location_facility: Bezmialem Vakf Üniversitesi-Oncology ( Site 1308)

location_facility: Providence Saint John's Health Center ( Site 0059)

location_facility: Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2808)

location_facility: Universitaetsklinikum Tuebingen ( Site 2405)

location_facility: Karolinska Universitetssjukhuset Solna ( Site 0802)

location_facility: Sapporo Medical University Hospital ( Site 3113)

location_facility: Georgetown University Medical Center ( Site 0023)

location_facility: Fejér Megyei Szent György Egyetemi Oktató Kórház-l.Pulmonologia ( Site 1407)

location_facility: Fundacion Arturo Lopez Perez FALP ( Site 2750)

location_facility: National Cancer Institute-Department of Minimally Invasive and Endoscopic Surgery, Interventional R

location_facility: Instituto Nacional del Cancer-CR Investigación ( Site 2753)

location_facility: Centre Hospitalier du Mans-Pneumologie ( Site 2527)

location_facility: Centre Hopitalier Intercommunal Creteil ( Site 2514)

location_facility: Shamir Medical Center Assaf Harofeh ( Site 2058)

location_facility: Korea University Anam Hospital ( Site 0956)

location_facility: Mount Sinai Medical Center Comprehensive Cancer Center ( Site 0031)

location_facility: Markusovszky Egyetemi Oktatokorhaz-Onkológiai Osztály ( Site 1410)

location_facility: Klaipeda University Hospital-Oncology chemotherapy ( Site 3302)

location_facility: Marmara Universitesi Pendik Egitim Arastirma Hastanesi-Medical Oncology ( Site 1305)

location_facility: Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre-Oncology ( Site 2809)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 1608)

location_facility: Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1606)

location_facility: National Hospital Organization Yamaguchi Ube Medical Center ( Site 3123)

location_facility: Hospital Universitari i Politecnic La Fe ( Site 0875)

location_facility: SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 3452)

location_facility: Chungnam national university hospital-Department of Internal Medicine ( Site 0958)

location_facility: UZ Leuven Gasthuisberg, Gynaecologie-Verloskunde ( Site 2907)

location_facility: Universitaetsklinikum Essen ( Site 2404)

location_facility: Bashkir State Medical University ( Site 1221)

location_facility: Hospital Universitario Puerta de Hierro-Majadahonda ( Site 0861)

location_facility: National Cancer Centre Singapore ( Site 2200)

location_facility: Mid Essex Hospitals Service Trust. Broomfield Hospital ( Site 0503)

location_facility: Tangdu Hospital of Fourth Military Medical University of Chi-department of radiotherapy ( Site 3455)

location_facility: Ad-Vance Medical Research-Research ( Site 1151)

location_facility: LungenClinic Grosshansdorf GmbH ( Site 2412)

location_facility: Azienda Ospedaliera Santa Maria ( Site 1962)

location_facility: National Cancer Center Hospital East ( Site 3121)

location_facility: China Medical University Hospital ( Site 3204)

location_facility: Princess Alexandra Hospital ( Site 3002)

location_facility: Hospital Universitario Insular de Gran Canaria ( Site 0867)

location_facility: Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1204)

location_facility: Medical Care and Research SA de CV ( Site 1103)

location_facility: AO Santa Maria della Misericordia-Oncology Department ( Site 1971)

location_facility: Powiatowe Centrum Zdrowia w Brzezinach Sp. z o. o. Oddział Dziennej Chemioterapii ( Site 1611)

location_facility: Hospital Clinic de Barcelona ( Site 0852)

location_facility: Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 1964)

location_facility: Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 1413)

location_facility: Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0877)

location_facility: Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2801)

location_facility: Oslo Universitetssykehus Ullevål-Avdeling for kreftbehandling, Ullevål ( Site 1452)

location_facility: Instituto Valenciano de Oncologia - IVO ( Site 0863)

location_facility: Canterbury Regional Cancer & Blood Service ( Site 1500)

location_facility: Udmurtian Republican Clinical Oncology Center ( Site 1212)

location_facility: Oslo Universitetssykehus Radiumhospitalet ( Site 1450)

location_facility: ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 1969)

location_facility: HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 0872)

location_facility: Kansai Medical University Hospital ( Site 3126)

location_facility: National Cancer Center Hospital ( Site 3130)

location_facility: Centro Medico San Roque-Oncology ( Site 1352)

location_facility: Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 0860)

location_facility: Sun Yat-sen University Cancer Center-melanoma ( Site 3482)

location_facility: The Cancer Institute Hospital of JFCR ( Site 3108)

location_facility: Parc de Salut Mar - Hospital del Mar-Oncologia ( Site 0873)

location_facility: Zala Megyei Szent Rafael Korhaz ( Site 1400)

location_facility: Taipei Veterans General Hospital ( Site 3202)

location_facility: Chonnam National University Hwasun Hospital-Hemato-Oncology ( Site 0959)

location_facility: Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1401)

location_facility: Northwest Georgia Oncology Centers PC ( Site 0061)

location_facility: Kaiser Permanente Moanalua Medical Center ( Site 0063)

location_facility: MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 3657)

location_facility: Istituto di Candiolo - IRCCS ( Site 1960)

location_facility: Affiliated Hospital of Military Medical Science Academy of the PLA ( Site 3465)

location_facility: Policlinico Universitario Agostino Gemelli ( Site 1965)

location_facility: The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 346

location_facility: St Vincent's Hospital-Oncology Clinical Trials ( Site 3018)

location_facility: Hospital General Universitario de Valencia ( Site 0854)

location_facility: University of Iowa Hospital and Clinics ( Site 0026)

location_facility: P. A. Hertsen Moscow Oncology Research Center ( Site 1214)

location_facility: Beijing Cancer hospital-Thoracic Cancer Department A ( Site 3454)

location_facility: Russian Scientific Center of Roentgenoradiology ( Site 1215)

location_facility: Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 1001)

location_facility: Baskent Universitesi Ankara Hastanesi ( Site 1303)

location_facility: Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2525)

location_facility: Clinica Universitaria de Navarra ( Site 0855)

location_facility: Tartu University Hospital-Radiotherapy and oncology ( Site 3800)

location_facility: Tampere University Hospital [Tampere Finland] ( Site 0600)

location_facility: Hiroshima University Hospital ( Site 3154)

location_facility: GBUZ LOKB-Oncology department #1 ( Site 1222)

location_facility: Bialostockie Centrum Onkologii ( Site 1610)

location_facility: FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 1208)

location_facility: Sunnybrook Research Institute ( Site 2802)

location_facility: Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 3300)

location_facility: ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 1008)

location_facility: Odense Universitetshospital ( Site 0650)

location_facility: Shanghai Pulmonary Hospital ( Site 3470)

location_facility: University of Colorado Cancer Center ( Site 0021)

location_facility: Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 3475)

location_facility: Dokkyo Medical University - Koshigaya Hospital ( Site 3152)

location_facility: South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)

location_facility: Hospital Tengku Ampuan Afzan ( Site 0627)

location_facility: Norrlands Universitetssjukhus ( Site 0800)

location_facility: Kanazawa University Hospital ( Site 3140)

location_facility: Tianjin Medical University Cancer Institute and Hospital ( Site 3456)

location_facility: London Regional Cancer Program - LHSC ( Site 2806)

location_facility: Grupo Medico Angeles-Grupo Medico Angeles ( Site 3402)

location_facility: INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1102)

location_facility: Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2004)

location_facility: Osaka Habikino Medical Center ( Site 3138)

location_facility: Helse Bergen Haukeland universitetssykehus ( Site 1451)

location_facility: Queen Mary Hospital-Department of Medicine (Respiratory) ( Site 1900)

location_facility: Jichi Medical University Hospital ( Site 3141)

location_facility: Helios Klinikum Emil von Behring Berlin-Zehlendorf-Lungenklinik Heckeshorn ( Site 2418)

location_facility: Trakya Universitesi Tip Fakultesi ( Site 1301)

location_facility: MedStar Franklin Square Medical Center ( Site 0046)

location_facility: Medizinische Universitaet Innsbruck ( Site 2951)

location_facility: Vanderbilt Ingram Cancer Center ( Site 0015)

location_facility: Nippon Medical School Hospital ( Site 3139)

location_facility: University of Texas MD Anderson Cancer Center ( Site 0007)

location_facility: Centro Hospitalar de Sao Joao - Hospital de Sao Joao ( Site 1752)

location_facility: Oaxaca Site Management Organization ( Site 1106)

location_facility: The Royal Marsden NHS Foundation Trust. ( Site 0513)

location_facility: Gallipoli Medical Research Foundation ( Site 3011)

location_facility: Kobe City Medical Center General Hospital ( Site 3144)

location_facility: RIGA EAST UNIVERSITY HOSPITAL ,Oncology Centre of Latvia-Out-patient and Day patient facility of Ch

location_facility: Blod och Tumorssjukdomar. Akademiska sjukhuset ( Site 0801)

location_facility: Providence Portland Medical Center ( Site 0051)

location_facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1955)

location_facility: Fujian Provincial Cancer Hospital ( Site 3461)

location_facility: SAIH of the Tyumen region, Multidisciplinary Clinical Medical Center "Medical town" ( Site 1220)

location_facility: National Cheng Kung University Hospital ( Site 3201)

location_facility: Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 2

location_facility: John Theurer Cancer Center at Hackensack University Medical Center ( Site 0038)

location_facility: CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0876)

location_facility: Ogarev Mordovia State University ( Site 1206)

location_facility: Hospital São Lucas da PUCRS-Centro de Pesquisa em Oncologia ( Site 1006)

location_facility: Hospital General Universitario 12 de Octubre ( Site 0856)

location_facility: Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház ( Site 1409)

location_facility: Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060)

location_facility: Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1411)

location_facility: Universitätsklinikum Erlangen ( Site 2408)

location_facility: Avix Investigación Clinica, S.C.-Oncology ( Site 1104)

location_facility: Belgorod Oncology Dispensary ( Site 1213)

location_facility: Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna

location_facility: Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1203)

location_facility: Hiroshima City Hiroshima Citizens Hospital ( Site 3119)

location_facility: Hôpitaux Universitaires de Genève (HUG) ( Site 0753)

location_facility: The Beatson West of Scotland Cancer Centre ( Site 0506)

location_facility: Odessa Regional Oncology Center ( Site 3655)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

location_facility: Universitatsklinikum Carl Gustav Carus ( Site 2407)

location_facility: Massachusetts General Hospital ( Site 0041)

location_facility: Ankara University Hospital Cebeci ( Site 1306)

location_facility: Osaka City General Hospital ( Site 3125)

location_facility: University of North Carolina at Chapel Hill ( Site 0040)

location_facility: Kochi Health Sciences Center ( Site 3145)

location_facility: Hangzhou Cancer Hospital-Medical Oncology ( Site 3468)

location_facility: Peter MacCallum Cancer Centre ( Site 3008)

location_facility: Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0703)

location_facility: Hospital Universitari Sant Joan de Reus-Oncology ( Site 0874)

location_facility: IRCCS A.O.U. San Martino - IST ( Site 1961)

location_facility: Hospital Nossa Senhora da Conceição ( Site 1011)

location_facility: Memorial Antalya Hospital-Oncology ( Site 1315)

location_facility: Fakultni nemocnice v Motole ( Site 0700)

location_facility: LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2005)

location_facility: Regional Budgetary Healthcare Institution 'Ivanovo Regional Oncology Dispensary'-Urology ( Site 1219

location_facility: Administradora Country S.A. ( Site 2701)

location_facility: Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 3466)

location_facility: Spitalul Județean Sfântul Ioan cel Nou Suceava-Oncology ( Site 3550)

location_facility: Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1402)

location_facility: Hospital Privado Universitario de Córdoba ( Site 1354)

location_facility: Istituto Europeo di Oncologia ( Site 1952)

location_facility: Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1201)

location_facility: Hospital Universitario Central de Asturias-Medical Oncology ( Site 0870)

location_facility: University of Arizona Cancer Center ( Site 0018)

location_facility: Hyogo Medical University Hospital ( Site 3100)

location_facility: Army Medical Center of People's Liberation Army-Oncology Department ( Site 3477)

location_facility: Clinical Research Center of specialized types medical care-Oncology ( Site 1205)

location_facility: Kitasato University Hospital ( Site 3142)

location_facility: Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1307)

location_facility: Yamaguchi University Hospital ( Site 3114)

location_facility: Cancer Institute of New Jersey ( Site 0025)

location_facility: Rambam Health Care Campus-Oncology Division ( Site 2053)

location_facility: Mayo Clinic in Rochester, Minnesota ( Site 0002)

location_facility: Instituto de Cancerología-Oncology ( Site 2702)

location_facility: Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1302)

location_facility: Kaohsiung Chang Gung Memorial Hospital ( Site 3203)

location_facility: SRH Wald-Klinikum Gera GmbH ( Site 2403)

location_facility: Cliniques Universitaires de Bruxelles - CUB - Hopital Erasme ( Site 2905)

location_facility: National Hospital Organization Shikoku Cancer Center ( Site 3116)

location_facility: Mater Misercordiae University Hospital ( Site 1800)

location_facility: National Hospital Organization Kyushu Medical Center ( Site 3136)

location_facility: CHU Toulouse - Hopital Rangueil ( Site 2518)

location_facility: Istanbul University Capa Campus ( Site 1314)

location_facility: Nara Medical University Hospital ( Site 3110)

location_facility: CH Lyon Sud Hospices Civils de Lyon ( Site 2521)

location_facility: Orszagos Koranyi Pulmonologiai Intezet ( Site 1403)

location_facility: Aichi Cancer Center Hospital ( Site 3101)

location_facility: Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022)

location_facility: Capital & Coast District Health Board - Wellington Hospital ( Site 1501)

location_facility: Sir Charles Gairdner Hospital ( Site 3006)

location_facility: IRCCS CRO Aviano, Hematology/Oncology ( Site 1957)

location_facility: National Hospital Organization Nagoya Medical Center ( Site 3109)

location_facility: Chaim Sheba Medical Center. ( Site 2052)

location_facility: Municipal non-profit enterprise "Kyiv City Clinical Oncology Center" of executive body of Kyiv City

location_facility: Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 1406)

location_facility: The First Hospital of Jilin University-Oncology ( Site 3464)

location_facility: Azienda Ospedaliera San Camillo Forlanini ( Site 1958)

summary:
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study.

This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will roll-over to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment.

Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.

status_simplified: Ongoing


title: Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

summary:
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials.

This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.

study_start_date_type: Actual

status: Completed

study_completion_date_type: Actual

study_type: Observational

time_perspective: Prospective

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M, Hofer H, Semmo N, Negro F, Zhang Z, Marcinak J, Veitsman E, Hazzan R, Mimidis K, Goulis I, Marques N, Flisiak R, Mazur W, Roncero C, Marra F, Pageaux GP, Asselah T, Lampertico P. Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infect Dis Ther. 2021 Dec;10(4):2203-2222. doi: 10.1007/s40121-021-00455-1. Epub 2021 Jun 14. Erratum In: Infect Dis Ther. 2021 Sep 16;:

ReferenceCitation: Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021 Jan 19;151:w20399. doi: 10.4414/smw.2021.20399. eCollection 2021 Jan 18.

ipd_sharing: Undecided

lead_sponsor: AbbVie

location_country: Poland Portugal Greece Austria Italy Switzerland France Israel Belgium

location_facility: Azienda Ospedaliera di Rilievo /ID# 168141

location_facility: Wilhelminenspital der Stadt Wien /ID# 169914

location_facility: Ctre Hospitalier de Tourcoing /ID# 202805

location_facility: Papageorgiou General Hospital Thessaloniki /ID# 207980

location_facility: Cabinet Medical, Boyer Darrigr /ID# 202050

location_facility: Tzaneio general hospital of Piraeus /ID# 208828

location_facility: Centre Hospitalier PERPIGNAN /ID# 205762

location_facility: Krakowski Szpital Specjalistyczny im. Jana Pawla II /ID# 208451

location_facility: Wojewódzki Szpital Zespolony w Kielcach /ID# 210569

location_facility: Gastroenterology Institute, Division of Medicine /ID# 169360

location_facility: Wojewodzki Szpit Bieganskiego /ID# 208445

location_facility: AOU Citta della Salute Scienza /ID# 168142

location_facility: AOU di Cagliari - Presidio di /ID# 168132

location_facility: CHU NANCY - Hopital Brabois Adultes /ID# 202570

location_facility: General Oncological Hospital of Kifisia Oi Agioi Anargyroi /ID# 206419

location_facility: Azienda Ospedaliera di Padova /ID# 168125

location_facility: Klinikum Klagenfurt am Woerthersee, Apotheke /ID# 169931

location_facility: Azienda Ospedaliero - Universi /ID# 168130

location_facility: Azienda Ospedaliera Luigi Sacc /ID# 168140

location_facility: Fondazione Epatocentro Ticino /ID# 201024

location_facility: Gen Univ Hosp Alexandroupolis /ID# 206416

location_facility: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 168137

location_facility: Azienda Ospedaliera Luigi Sacc /ID# 168136

location_facility: Università Cattolica Sacro Cuore /ID# 168781

location_facility: Medizinische Universität Graz /ID# 169932

location_facility: Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 208604

location_facility: Specjalistyczny Szpital im. dra Alfreda Sokolowskiego /ID# 208862

location_facility: IBD Center - IRCCS Istituto Clinico Humanitas /ID# 169353

location_facility: Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 207910

location_facility: Hopital de la Cavale Blanche /ID# 202640

location_facility: Centre Hospitalier de Béziers /ID# 202948

location_facility: Azienda Ospedaliera di Padova /ID# 168126

location_facility: Hospital Garcia de Orta, E.P.E /ID# 207717

location_facility: A.O.U. Policlinico G. Martino /ID# 168139

location_facility: Centre Hospitalier de Wallonie Picarde /ID# 200822

location_facility: NZOZ Przychodnia Specjalistycz /ID# 208334

location_facility: Azienda Ospedaliera Maggiore d /ID# 168710

location_facility: Klinikum Wels - Grieskirchen /ID# 169916

location_facility: MED-FIX Centrum Medyczne Sp. z /ID# 208453

location_facility: Universita degli Studi della /ID# 168135

location_facility: Centre Hosp Intercommunal de Creteil /ID# 202566

location_facility: Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 168711

location_facility: ASST Grande Ospedale Metropolitano Niguarda /ID# 168712

location_facility: Inselspital, Universitaetsklinik /ID# 201022

location_facility: CH Annecy Genevois Site Annecy /ID# 202804

location_facility: General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206414

location_facility: Algemeen Stedelijk Ziekenhuis /ID# 170876

location_facility: Ctre Hospitalier de Tourcoing /ID# 202358

location_facility: Assaf Harofeh Medical Center /ID# 169370

location_facility: Hopitaux Universitaires de Geneve /ID# 203435

location_facility: Centro Hospitalar Universitário Lisboa Central, EPE - Hospital Curry Cabral /ID# 208463

location_facility: Azienda Universitaria Ospedali /ID# 168129

location_facility: Universitair Ziekenhuis Leuven /ID# 170921

location_facility: General Hospital Nikaias-Piraeus St. Panteleimon /ID# 206420

location_facility: Centro Hospitalar Barreiro Montijo, EPE /ID# 211267

location_facility: University Hospital St. Polten /ID# 169918

location_facility: General Hospital of Athens Laiko /ID# 206421

location_facility: CHR Orleans - Hopital de la Source /ID# 202360

location_facility: AOU OO. RR. San Giovanni di Di /ID# 168715

location_facility: Wojewodzki Szpital Obserwacyjn /ID# 209345

location_facility: ASST Grande Ospedale Metropolitano Niguarda /ID# 168138

location_facility: Wojewodzki Szpit Bieganskiego /ID# 209608

location_facility: CHU de Besancon - Jean Minjoz /ID# 208502

location_facility: Cabinet Medical, Dr. Constant, /ID# 202361

location_facility: Centro Hospitalar do Porto EPE /ID# 207733

location_facility: Fondazione PTV Policlinico Tor Vergata /ID# 168709

location_facility: Centro Hospitalar Vila Nova Gaia/Espinho, EPE /ID# 208195

location_facility: Hopital Bichat-Claude Bernard /ID# 202513

location_facility: KH der Elisabethinen Linz GmbH /ID# 169915

location_facility: Centre Hospitalier Universitaire de Grenoble - Hopital Michallon /ID# 202957

location_facility: Szpital Specjalistyczny W Chorzowie /Id# 209129

location_facility: Ospedale Sant Orsola Malpighi /ID# 168127

location_facility: Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 170930

location_facility: NZOZ - Lubuska Specjalistyczna Poradnia Chorób Wątroby Sp. z o.o. /ID# 208449

lead_sponsor_type: industriel

status_simplified: Completed


title: Global PANORAMA Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC.

acronym: PANORAMA

summary:
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer).

Patients will be recruited from participating sites in Europe, Asia, and Canada. The study will include 2 patient cohorts.

status: Terminated

lead_sponsor: AstraZeneca

location_country:
Taiwan
Spain
United Kingdom
Canada
France
China

intervention_type: Other

status_simplified: Unknown


title: Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia

acronym: LGL

summary:
LGL leukemia represents a rare subtype of chronic T or NK lymphoproliferative disorders. It is an indolent disease, the main hematological or autoimmune complications lead to a treatment in more than 60% of patients.

Investigators set up at the University Hospital of Rennes, a database of more than 300 patients with LGL leukemia from major French services that support this disease, and published in 2010 the largest series of patients in the world (n = 229). However, the limited heterogeneity and retrospective data collected, as all previously released, makes it difficult the proposal of consensual treatment options. If first and second line treatments are based on the use of immunosuppression with methotrexate, cyclophosphamide, or cyclosporin A, no molecule has proven superiority over others. Methotrexate and cyclophosphamide are mainly used in the first line. Invetigators just have in the literature data on about 100 patients treated with either of these drugs. Combining the results of our series with those in the literature, invetigators estimate the respective overall response rate (RG) and complete response rate (CR) in 55% and 30% for methotrexate, and 60% and 50% for cyclophosphamide.

Thus, there are four objective in this study :

to compare the respective efficacies of methotrexate and cyclophosphamide when administered as first-line therapies in patients suffering from T/NK LGL leukemia with severe neutropenia or neutropenia associated with infections, and/or anemia requiring transfusions, and/or auto-immune associated disease
to evaluate the percentage of patients refractory to methotrexate or cyclophosphamide for which a second line treatment is efficacious
to explore, in case of non-response to the first-line therapy, the efficacy of ciclosporine A, the comparison being performed with the treatment which was not administered in the first-line therapy
to evaluate the response rate according to the phenotypic subtype of LGL leukemia.

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Anticipated

lead_sponsor: Rennes University Hospital

location_facility: Hematology Service - CH de la cote basque

location_facility: Hematology Service - Hopital La Pitié Salpetrière

location_facility: Hematology Service - CH François Baclesse

location_facility: Oncology Unit - Institut de cancérologie de la Loire

location_facility: Hematology Unit CH Notre Dame Bon Secours

location_facility: Hematology Service - CH Docteur Duchenne

location_facility: Hôpital André Mignot Centre Hospitalier de Versailles

location_facility: Intern medecine Service - CH Antibes-Juan-les-Pins

location_facility: CHU Henri Mondor Lymphoid Hemopathy Unit

location_facility: Hematology Unit - Institut Paoli-Calmettes

intervention_type: Drug

lead_sponsor_type: academique


title: IMPACT OF COMORBITIES ON HEMOGLOBIN STABILITY IN CHONIC KIDNEY DISEASE PATIENTS ON DIALYSIS TREATED WITH C.E.R.A

summary: This prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with Mircera (methoxy polyethylene glycol-epoetin beta). Eligible patients will be followed for 6 months of treatment.

lead_sponsor: Hoffmann-La Roche


title: A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA."

lead_sponsor: Nantes University Hospital

type: EudraCT Number

source: euctr

location_facility: Centre Hospitalier intercommunale Meulan les mureaux

location_facility: Centre Hospitalier de la région d'Annecy

summary:
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib) Cyclophosphamide Dexamethasone (VCD) as an Induction Treatment prior to Autologous Stem Cell Transplantation in patients with Newly Diagnosed Multiple Myeloma.

Eligible patients will be randomized into 2 treatment arms. Each patient will receive 4 consecutive 21 day cycles of an induction treatment with either VTD or VCD.


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

acronym: Bridalveil

summary:
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

ipd_sharing_description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

lead_sponsor: Gilead Sciences

location_country:
Poland
Taiwan
Spain
Italy
Russian Federation
Australia
United Kingdom
Canada
Sweden
Korea, Republic of
United States
France
Israel
Germany
Czechia

location_facility: N. N. Blokhin Russian Cancer Research Center

location_facility: Hadassah Medical Organization, Ein Kerem

location_facility: Joliet Oncology Hematology Associates Ltd.

location_facility: Szpital Kliniczny nr 1, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku

location_facility: State Budgetary Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary #1"

location_facility: Haematology and Oncology Clinics of Australia Gold Coast

location_facility: Centre Hospitalier Universitaire de Strasbourg - Hôpital Hautepierre

location_facility: Azienda Ospedaliera Ospedali Riuniti Marche Nord

location_facility: Gemeinschaftspraxis Dres. Söling Und Siehl

location_facility: University College London Hospitals National Health Society Foundation Trust

location_facility: Centre Hospitalier Universitaire de Sherbrooke

location_facility: Saint Petersburg I.P. Pavlov State Medical University

location_facility: Centralny Szpital Kliniczny MSW w Warszawie

location_facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino

location_facility: Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko

location_facility: Queen Elizabeth II Health Sciences Centre, Centre for Clinical Research

location_facility: FGU Russian Scientific Research Institute of Hematology and Transfusiology

location_facility: Centre Hospitalier Affilie Universitaire de Quebec

location_facility: Comprehensive Blood and Cancer Center (Bakersfield)

location_facility: Sverdlovsk Regional Clinical Hospital #1

location_facility: Guys and Saint Thomas NHS Foundation Trust

location_facility: Hospital Universitari i Politecnic La Fé de Valencia

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim

location_facility: North Shore Hematology/Oncology Associates

location_facility: Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku

location_facility: Hospital Clínico Universitario de Salamanca

location_facility: Signal Point Clinical Research Center, LLC

location_facility: Kaiser Permanente Vallejo Medical Center

location_facility: Centre Hospitalier Régional et Universitaire - Hôpital Bretonneau

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Klinikum der Ludwig-Maximilians-Universität München

location_facility: Spedali Civili Di Brescia Azienda Ospedaliera

location_facility: Azienda Ospedaliera Ospedale Niguarda Ca' Granda

location_facility: Sylvester Comprehensive Cancer Center/UMHC

location_facility: Hospital General Universitario Gregorio Marañon

location_facility: Centre Hospitalier Universitaire de Poitiers

location_facility: Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

location_facility: IRCCS Azienda Ospedaliera Universitaria San Martino

location_facility: Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi

location_facility: Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto

location_facility: Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi

location_facility: Centre Hospitalier Départmental La Roche sur Yon

location_facility: Froedtert Hospital and Medical College of Wisconsin

location_facility: FSI "V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies"

location_facility: Azienda Ospedaliero Universitaria (AOU) "Maggiore della Carita" di Novara

location_facility: Centro di Riferimento Oncologico di Aviano

location_facility: Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte


title: Evaluation of Risk Factors Associated With Intracranial Aneurysm Recanalization After Endovascular Treatment

acronym: ARETA

summary:
Endovascular treatment is now the first line treatment for the management of intracranial aneurysms. However aneurysm recanalization is an important limitation to this treatment. Several factors seems to be associated with aneurysm recanalization including medical history of the patient, aneurysm status (ruptured or unruptured), aneurysm size and location, modalities of treatment, immediate post-operative occlusion of the aneurysm.

A precise knowledge of factors increasing the risk of aneurysm recanalization is quite important to optimize strategy of treatment and reduce the recanalization rate. No large, prospective, multicenter trial dealing with this question has been published in the literature.

ReferenceCitation: Pierot L, Barbe C, Thierry A, Bala F, Eugene F, Cognard C, Herbreteau D, Velasco S, Chabert E, Desal H, Aggour M, Rodriguez-Regent C, Gallas S, Sedat J, Marnat G, Sourour N, Consoli A, Papagiannaki C, Spelle L, White P. Patient and aneurysm factors associated with aneurysm recanalization after coiling. J Neurointerv Surg. 2022 Nov;14(11):1096-1101. doi: 10.1136/neurintsurg-2021-017972. Epub 2021 Nov 5.

ReferenceCitation: Pierot L, Barbe C, Herbreteau D, Gauvrit JY, Januel AC, Bala F, Ricolfi F, Desal H, Velasco S, Aggour M, Chabert E, Sedat J, Trystram D, Marnat G, Gallas S, Rodesch G, Clarençon F, Papagiannaki C, White P, Spelle L; From the Departments of Neuroradiology, Research, and Public Health. Immediate post-operative aneurysm occlusion after endovascular treatment of intracranial aneurysms with coiling or balloon-assisted coiling in a prospective multicenter cohort of 1189 patients: Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm (ARETA) Study. J Neurointerv Surg. 2021 Oct;13(10):918-923. doi: 10.1136/neurintsurg-2020-017012. Epub 2020 Dec 21.

ReferenceCitation: Pierot L, Barbe C, Herbreteau D, Gauvrit JY, Januel AC, Bala F, Ricolfi F, Desal H, Velasco S, Aggour M, Chabert E, Sedat J, Trystram D, Marnat G, Gallas S, Rodesch G, Clarençon F, Papagiannaki C, White P, Spelle L. Delayed thromboembolic events after coiling of unruptured intracranial aneurysms in a prospective cohort of 335 patients. J Neurointerv Surg. 2021 Jun;13(6):534-540. doi: 10.1136/neurintsurg-2020-016654. Epub 2020 Sep 7.

ReferenceCitation: Pierot L, Barbe C, Herbreteau D, Gauvrit JY, Januel AC, Bala F, Ricolfi F, Desal H, Velasco S, Aggour M, Chabert E, Sedat J, Trystram D, Marnat G, Gallas S, Rodesch G, Clarençon F, Papagiannaki C, White P, Spelle L. Rebleeding and bleeding in the year following intracranial aneurysm coiling: analysis of a large prospective multicenter cohort of 1140 patients-Analysis of Recanalization after Endovascular Treatment of Intracranial Aneurysm (ARETA) Study. J Neurointerv Surg. 2020 Dec;12(12):1219-1225. doi: 10.1136/neurintsurg-2020-015971. Epub 2020 Jun 16.

ReferenceCitation: Pierot L, Barbe C, Ferré JC, Cognard C, Soize S, White P, Spelle L. Patient and aneurysm factors associated with aneurysm rupture in the population of the ARETA study. J Neuroradiol. 2020 Jun;47(4):292-300. doi: 10.1016/j.neurad.2019.07.007. Epub 2019 Sep 17.

lead_sponsor: CHU de Reims

location_facility: Centre Hospitalier Universitaire de Reims

location_facility: Centre Hospitalier Universitaire de Besançon

intervention_type: Device


title: A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER

acronym: ESMERALDA

summary:
The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra toxicities.

It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.

lead_sponsor: ARCAGY/ GINECO GROUP

location_facility: Hôpital Privé Drôme Ardèche - Clinique Pasteur

location_facility: Centre Hospitalier de la Région d'Annecy

location_facility: Centre de Radiothérapie - Clinique Sainte-Anne

location_facility: Hôpital Morvan - Centre Hospitalier Universitaire

location_facility: Centre Hospitalier Privé de Saint-Grégoire

location_facility: Institut Curie - Hopital Claudius Régaud


title: A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders

acronym: MEMENTO

summary: A Multicenter national prospective cohort study including at least 2300 individuals consecutively recruited from French Research Memory Centers and followed-up over 5 years.

ReferenceCitation: Blanc F, Bouteloup V, Paquet C, Chupin M, Pasquier F, Gabelle A, Ceccaldi M, de Sousa PL, Krolak-Salmon P, David R, Fischer C, Dartigues JF, Wallon D, Moreaud O, Sauvée M, Belin C, Harston S, Botzung A, Albasser T, Demuynck C, Namer I, Habert MO, Kremer S, Bousiges O, Verny M, Muller C, Philippi N, Chene G, Cretin B, Mangin JF, Dufouil C. Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort. Alzheimers Res Ther. 2022 Jul 19;14(1):96. doi: 10.1186/s13195-022-01037-0.

ReferenceCitation: Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, Hanon O, Dartigues JF, Harston S, Gabelle A, Ceccaldi M, Beauchet O, Krolak-Salmon P, David R, Rouaud O, Godefroy O, Belin C, Rouch I, Auguste N, Wallon D, Benetos A, Pariente J, Paccalin M, Moreaud O, Hommet C, Sellal F, Boutoleau-Bretonniére C, Jalenques I, Gentric A, Vandel P, Azouani C, Fillon L, Fischer C, Savarieau H, Operto G, Bertin H, Chupin M, Bouteloup V, Habert MO, Mangin JF, Chêne G; MEMENTO cohort Study Group. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017 Aug 29;9(1):67. doi: 10.1186/s13195-017-0288-0.

lead_sponsor: University Hospital, Bordeaux

location_facility: CHU de Saint-Etienne - Hôpital de la charité

location_facility: CHU de Bordeaux - Hôpital Xavier-Arnozan


type: Other Identifier

title: Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation.

acronym: MITRA-FR

summary:
The objective of this trial is to compare the safety, the efficacy and the cost-effectiveness of 2 therapeutic strategies (optimal standard of care therapy alone versus percutaneous MitraClip procedure and optimal standard of care therapy) in patients with severe secondary mitral regurgitation.

This trial is a French, multicenter and randomized trial. Patients enrolled will be clinically followed for 2 years (phone call at 1 month, clinical visit at 6 months, 12 months and 24 months).

status: Unknown status

ReferenceCitation: Iung B, Messika-Zeitoun D, Boutitie F, Trochu JN, Armoiry X, Maucort-Boulch D, Obadia JF, Vahanian A. Characteristics and Outcome of COAPT-Eligible Patients in the MITRA-FR Trial. Circulation. 2020 Dec 22;142(25):2482-2484. doi: 10.1161/CIRCULATIONAHA.120.049743. Epub 2020 Dec 21.

ReferenceCitation: Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, Brochet E, Thibault H, Piriou N, Cormier B, Tribouilloy C, Guerin P, Lefèvre T, Maucort-Boulch D, Vahanian A, Boutitie F, Obadia JF. Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After MitraClip Implantation: Results From the Mitra-FR Trial. JACC Cardiovasc Imaging. 2021 Apr;14(4):742-752. doi: 10.1016/j.jcmg.2020.07.021. Epub 2020 Sep 16.

ReferenceCitation: Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, Lefèvre T, Messika-Zeitoun D, Guerin P, Cormier B, Brochet E, Thibault H, Himbert D, Thivolet S, Leurent G, Bonnet G, Donal E, Piriou N, Piot C, Habib G, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M, Samson G, Rioufol G, Maucort-Boulch D, Obadia JF; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019 Dec;21(12):1619-1627. doi: 10.1002/ejhf.1616. Epub 2019 Nov 18.

ReferenceCitation: Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N; MITRA-FR Investigators. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018 Dec 13;379(24):2297-2306. doi: 10.1056/NEJMoa1805374. Epub 2018 Aug 27.

lead_sponsor: Hospices Civils de Lyon

location_facility:
Institut Hospitalier Jacques Cartier
Clinique Cardiologique Saint Gatien
Hôpital Gabriel Montpied
Hôpital Nord
Chu de Nantes
Clinique Du Millenaire
Chu de Nancy
CHRU La Cavale Blanche
Chu de Strasbourg
Institut Mutualiste Montsouris
Chu de Bordeaux
Groupe Hospitalier La Salpétrière
APHP Hôpital Henri Mondor
Hôpital privé de Parly 2
Hôpital privé le Bois
CHRU de Tours
Centre Chirurgical Marie Lannelongue
Clinique Pasteur
Chu de Besancon
Chu de Montpellier
Institut Arnault Tzanck
Centre Cardiologique du Nord
CHU Rouen
Clinique du Tonkin
Chu de Toulouse
Hôpital Européen Georges Pompidou
CH Annecy Genevois
Hopital de La Timone
CHRU La Milétrie
Chu de Lille
Hôpital Pasteur
Groupement Hospitalier Est
Centre chirurgicale Ambroise Paré
CHU Caen
Hôpital Saint-Joseph
Aphp Hopital Bichat
Hôpital privé Clairval
Chu de Rennes
CHU d'Angers
CHU de Grenoble


acronym: APNEE REA

summary: Clinical diagnostic of brain death requires a non-reactive coma, absence of brain stem reflex, and absence of spontaneous breathing. The confirmation of absence of spontaneous breathing is established the apnea test (according to the American Academy of Neurology's Guidelines). However this test may lead to complications (acute hypoxemia, ventilatory and cardiocirculatory disorders) and reduces significantly the number of lung transplants. Some data suggest modifying the apnea test : replace the ventilator switching off with continuous positive airway pressure (CPAP) use. These studies showed that this alternative method (CPAP) increased the level of lung harvest but they were not sufficient because these studies were monocentric with little patients,. That why the aim of the present study is to compare the standard strategy and CPAP strategy with a prospective, multicenter,cluster trial; each center will use the method of apnea test which it uses usually.

lead_sponsor: Poitiers University Hospital

location_facility:
Toulon University Hospital
Orléans Hospital
Poitiers University Hospital
Sud Francilien Hospital
Saintes Hospital
Tours University Hospital
Angoulême Hospital
Brest University Hospital
Cochin University Hospital
Rennes University hospital
Limoges University Hospital
La Rochelle Hospital
Nice University Hospital
La Roche sur Yon Hospital
Bordeaux University Hospital
Angers University Hospital
Nantes University Hospital

intervention_type: Procedure


intervention_type: Biological

title: Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.

lead_sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

ReferenceCitation: Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M, André T, de Gramont A. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015 Jul 4;15:496. doi: 10.1186/s12885-015-1503-7.

location_country: France Israel Ireland

location_facility: Centre d'oncologie et de radiothérapie du Parc

location_facility: Institut de Cancérologie Lucien Neuwirth

location_facility: Adelaide & Meath Hospital Dublin ( AMNCH)

summary: STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.


acronym: ECLIPSE

title: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

lead_sponsor: Novartis Pharmaceuticals

summary: The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.


title: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock

acronym: CLOTILDE

summary: The size of the acute myocardial infarction (AMI) is related to ischemia and injury induced by tissue reperfusion. These reperfusion's injuries can be reduced by injection of cyclosporin A (CsA) at the time of reperfusion. This post-conditioning reduces the final infarct size 20 to 40%. This has been demonstrated in STEMI patients non-complicated by cardiogenic shock. Early revascularization in the AMI complicated by cardiogenic shock improves short-term and long term survival by reducing the size of the myocardial infarction. The hypothesis of this study is that the administration of Cyclosporin A to these patients, in addition to mechanical reperfusion, is likely to reduce the severity of the multi-organ failure associated with the cardiogenic shock and improve clinical outcome.

status: Withdrawn

location_facility:
Chu de Bordeaux
Centre Hospitalier de Pau
Chu Hopital A Michallon
CH Pays d'Aix
Hôpital Gabriel Montpied
Aphp Hopital Bichat
Hopital Guillaume Et Rene Laennec
Chu de Nimes
Chu Arnaud de Villeneuve
Clinique de La Fourcade
Nouvel Hôpital Civil
Chu de Rangueil
Chru de Tours
Chu de Nancy Brabois
Hopital St Luc St Joseph
CHU Hopital Cardiologique Louis Pradel
Hopital Charles Nicolle
Chu Hopital Du Bocage


title: Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.

summary: This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.

location_facility: Clinique sainte marie; chimiotherapie ambulatoire

location_facility: Centre Hospitalier Lyon Sud; Pneumologie

location_facility: Gh Mutualiste Les Portes Du Sud; Pneumologie

location_facility: Chi Emile Durkheim Site Epinal; Pneumologie

location_facility: Clinique Saint Hilaire; Sce Chimiotherapie

location_facility: Centre Hospitalier Fleyriat; Oncologie/Hematologie

location_facility: Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale

location_facility: Hopital Saint Vincent; Consult et Explorations

location_facility: Groupe Oncorad Garonne; Unite Onco Hematologie

location_facility: Centre Alexis Vautrin; Oncologie Medicale

location_facility: Centre Hospitalier François Quesnay; Pneumologie-Neurologie

location_facility: Hopitaux Du Leman Site Thonon; Pneumologie

location_facility: Chi Alpes Du Sud Site De Gap; Pneumologie

location_facility: Hopital Gabriel Montpied; Service de Pneumologie

location_facility: Centre Oscar Lambret; Chir Cancerologie General

location_facility: Ch De Brive La Gaillarde; Radiotherapie Oncologie

location_facility: Centre Hospitalier Intercommunal; Service de Pneumologie

location_facility: Centre Cardiologique Du Nord; Pneumologie

location_facility: Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE

location_facility: Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie

location_facility: Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire

location_facility: Hopital Cochin; Unite Fonctionnelle D Oncologie

location_facility: Ch De Rambouillet; Pneumologie Cardiologie

location_facility: Hopital Du Cluzeau; Service de Pathologie Respiratoire

location_facility: Centre Hospitalier Alpes Leman CHAL;Pneumologie

location_facility: Hopital de Pontchaillou; Service de Pneumologie

location_facility: Hopital Louis Pasteur; Pneumologie Tabacologie

location_facility: Hopital Calmette; Pneumologie Oncologie Ouest

location_facility: Centre Medical National Mgen; Pneumologie

location_facility: Hopital Bel Air; Pneumologie Allergologie

location_facility: Ch Bretagne Sud Site Scorff; Oncologie Medicale

location_facility: Hôpital Saint Joseph; Oncologie Medicale

location_facility: CH Du Cotentin Site De Cherbourg; Hopital De Jour


title: Duration of Mechanical Ventilation and Mortality Among Brain-injured Patients - a Before-after Evaluation of a Quality Improvement Project

acronym: BI-VILI

summary:
Protective ventilation (association of a tidal volume < 8 ml/kg with a positive end expiratory pressure) is poorly used in severe brain-injured patients. Moreover, a systematic approach to extubation may decrease the rate of extubation failure and enhance outcomes of brain-injured patients.

We hypothesized that medical education and implementation of an evidence-base care bundle associating protective ventilation and systemic approach to extubation can reduce the duration of mechanical ventilation in brain-injured patients.

ReferenceCitation: Asehnoune K, Mrozek S, Perrigault PF, Seguin P, Dahyot-Fizelier C, Lasocki S, Pujol A, Martin M, Chabanne R, Muller L, Hanouz JL, Hammad E, Rozec B, Kerforne T, Ichai C, Cinotti R, Geeraerts T, Elaroussi D, Pelosi P, Jaber S, Dalichampt M, Feuillet F, Sebille V, Roquilly A; BI-VILI study group. A multi-faceted strategy to reduce ventilation-associated mortality in brain-injured patients. The BI-VILI project: a nationwide quality improvement project. Intensive Care Med. 2017 Jul;43(7):957-970. doi: 10.1007/s00134-017-4764-6. Epub 2017 Mar 18.

location_facility: Tours Univeristy Hospital - Neurosurgery ICU

location_facility: Tours University Hospital - Neurotrauma ICU


title: GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.

acronym: GASTRICHIP

summary:
A prospective, opened, multicentric, randomised, phase III trial with two arms:

Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
Arm B: curative gastrectomy with D1-D2 lymph node dissection

Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 and/or N+ and/or with positive peritoneal cytology), treated either with curative gastrectomy and adjuvant HIPEC, or with curative gastrectomy alone.

status: Active, not recruiting

ReferenceCitation: Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, Piaton E, Garofalo A. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014 Mar 14;14:183. doi: 10.1186/1471-2407-14-183.

location_country: France Spain

location_facility: Service de Chirurgie Viscérale, CHU Estaing

location_facility: Service de Chirurgie Digestive Oncologique, CLCC Alexis Vautrin

location_facility: Service de Chirurgie Digestive, Hôpital Jean Minjoz, CHU Besançon

location_facility: Service de Chirurgie Digestive, Hôpital du Bocage

location_facility: Service de Chirurgie Digestive et de l'Urgence, Hôpital Michallon

location_facility: Service de Chirurgie Viscérale et Digestive, Hôpital de Hautepierre

location_facility: Service de Chirurgie Digestive, Institut Curie

location_facility: Hospital Universitario Principe de Asturias

location_facility: Service de Chirurgie Digestive, Hôpital Lariboisière

location_facility: Service de Chirurgie Générale et Digestive, Hôpital Saint-Antoine, APHP

location_facility: Service de Chirurgie Digestive, Hôpital Nord

location_facility: Service de Chirurgie Viscérale et Oncologique, Hôpital Saint-Louis

location_facility: Service de Chirurgie Générale Digestive et Endocrinienne, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon

location_facility: Service de Chirurgie Digestive Oncologique, CLCC Paul Papin

location_facility: Service de Chirurgie Digestive, CLCC René Gauducheau

location_facility: Service de Chirurgie Générale et Digestive, Hôpital Purpan

location_facility: Service de Chirurgie Digestive et de Physiologie Digestive, Hôpital Ch. Nicolle

location_facility: Service de Chirurgie Viscérale, CHU de Poitiers

location_facility: Département de Chirurgie Digestive - CHU d'Angers

location_facility: Service de Chirurgie Digestive, CRLC Val d'Aurelle

location_facility: Service d'Oncologie Digestive, Hôpital de la Timone

location_facility: Service de Chirurgie Digestive et Générale, Hôpital Huriez

location_facility: Service de Chirurgie Digestive, CLCC Léon Bérard

location_facility: Service de Chirurgie Générale et Viscérale, CHU de Reims - Hôpital Robert Debré

location_facility: Département de Chirurgie Digestive, CHU d'Amiens

location_facility: Département de Chirurgie Digestive et Hépatobiliaire, Institut Gustave Roussy

location_facility: Service de Chirurgie Digestive, Hôpital Archet II

location_facility: Service de Chirurgie Viscérale, CLCC François Baclesse


title: Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.

acronym: OCTOPUS

summary:
The combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. The analysis of the literature reveals a lack of comparison of the associations of non-opioid analgesic (NOA) with morphine for postoperative analgesia.

The objectives of this study are :

comparing the morphine sparing effect of different combination of 3 NOA (paracetamol, nefopam, ketoprofen) for postoperative analgesia.
determining whether the morphine-sparing effect is associated with or without a reduction in the incidence of morphine side effects.
evaluating the effects of NOA on postoperative hyperalgesia.

ReferenceCitation: Beloeil H, Albaladejo P, Sion A, Durand M, Martinez V, Lasocki S, Futier E, Verzili D, Minville V, Fessenmeyer C, Belbachir A, Aubrun F, Renault A, Bellissant E; OCTOPUS group. Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: the OCTOPUS study. Br J Anaesth. 2019 Jun;122(6):e98-e106. doi: 10.1016/j.bja.2018.10.058. Epub 2018 Dec 29.

location_facility:
Emmanuel Marret
Sébastien Bloc
Jean-Xavier Mazoit
Pierre Albaladejo
Xavier Capdevila
Frédéric Aubrun
Jacques Ripart
Marc Raucoules
Jean-Marc Malinovsky
Vincent Minville
Hervé Bouaziz
Marc Gentili
Anissa Belbachir
Karim Asehnoune
Marcel Chauvin
Marc Beaussier
Karine Nouette-Gaulain
Hawa Keita-Meyer
Dominique Fletcher


acronym: ADDONIS

title: Randomized, Open-label, SU-controlled Study of 24-week Duration to Compare Metformin/Vildagliptin + Basal Insulin Versus Metformin/SU + Basal Insulin in T2DM Patients Starting Basal Insulin After Failing Metformin/SU

summary: To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.


acronym: ROSEWOOD

title: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

lead_sponsor: BeiGene

ReferenceType: background

ReferenceCitation: Trotman J, Folwer N, Auer R, Flowers C, Reed W, Stern JC, Huang J, Zinzani PL. Phase 2 Obinutuzumab Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Clinical Oncology, 2018.

ReferenceCitation: Fowler N, Trotman J, Auer R, Flowers C, Reed W, Marimpietri C, Huang J, Zinzani PL.Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab (obi) vs obi monotherapy in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL). American Society of Clinical Oncology. 2019

ReferenceCitation: Fowler NH, Trotman J, Auer R, Flowers CR, Reed WF, Ivanova E, Huang J, Zinzani PL.Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology. 2019

location_country:
Poland
Taiwan
Belarus
Spain
Italy
Russian Federation
Australia
New Zealand
Canada
United Kingdom
Korea, Republic of
United States
France
China
Germany
Bulgaria
Czechia

location_facility: N. N. Blokhin Russian Cancer Research Center

location_facility: Centre de Lutte Contre le Cancer - Institut Bergonie

location_facility: Centre Hospitalier Universitaire de Poitier- Hopital de la Miletrie - Hopital Jean Bernard

location_facility: Chonnam National University Hwasun Hospital

location_facility: Hospital Universitario Quironsalud Madrid

location_facility: Wojewódzki Szpital Specjalistyczny w Legnicy

location_facility: Soon Chun Hyang University Hospital Seoul

location_facility: Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev

location_facility: Second Affiliated Hospital of Army Medical University, PLA (Xinqiao Hospital)

location_facility: Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie - Oddział w Gliwicach

location_facility: State Budgetary Healthcare Institution. Volgograd

location_facility: Minsk City Clinical Oncological Dispensary

location_facility: Harbin Medical University Cancer Hospital

location_facility: Norfolk and Norwich University Hospitals NHS Foundation Trust

location_facility: University Multiprofile Hospital for Active Treatment Alexandrovska

location_facility: Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi

location_facility: Vitebsk Regional Clinical Oncology Dispensary

location_facility: Tongji Hospital of Tongji Medical College Huazhong University of Science Technology

location_facility: FGU Russian Scientific Research Institute of Hematology and Transfusiology

location_facility: The First Affiliated Hospital of College of Medicine, Zhejiang University

location_facility: IRCCS Ospedale di Circolo e Fondazione Macchi

location_facility: Tianjin Medical University Cancer Institute & Hospital

location_facility: State Healthcare Institution Oncologic Dispensary No. 2 - Health Department of Krasnodar Region

location_facility: Severance Hospital, Yonsei University Health System

location_facility: The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

location_facility: Nanfang Hospital,Southern Medical University

location_facility: Centre Hospitalier Universitaire de Nancy - Hôpital de Brabois

location_facility: Seoul National University Bundang Hospital

location_facility: Gomel Regional Clinical Oncology Dispensary

location_facility: Keimyung University Dongsan Medical Center

location_facility: Nizhniy Novgorod Regional Clinical Hospital N.A.

location_facility: N.N. Alexandrov National Cancer Centre of Belarus

location_facility: Hospital Universitario Puerta de Hierro - Majadahonda

location_facility: Azienda Unita Sanitaria Locale di Ravenna Ospedale Santa Maria delle Croci

location_facility: University of Illinois Hospital & Health Sciences System

location_facility: Taipei Medical University - Shuang Ho Hospital

location_facility: Institut Català d'Oncologia de l'Hospitalet de Llobregat

location_facility: University Multiprofile Hospital for Active Treatment Saint Ivan Rilski

location_facility: Centre Hospitalier Universitaire d'Amiens - Hopital Sud

summary: The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

summary: The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

ReferenceCitation: Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5.

ipd_sharing: No

lead_sponsor: Exelixis

location_country:
Croatia
Spain
Italy
United Kingdom
United States
Romania
Belgium
Czechia
Poland
Hong Kong
Austria
Australia
Russian Federation
Argentina
Israel
Mexico
Brazil
Canada
Hungary
Germany
Taiwan
Thailand
Korea, Republic of
France
Netherlands

location_facility:
Exelixis Clinical Site #29
Exelixis Clinical Site #31
Exelixis Clinical Site #160
Exelixis Clinical Site #13
Exelixis Clinical Site #85
Exelixis Clinical Site #136
Exelixis Clinical Site #4
Exelixis Clinical Site #1
Exelixis Clinical Site #112
Exelixis Clinical Site #60
Exelixis Clinical Site #127
Exelixis Clinical Site #48
Exelixis Clinical Site #91
Exelixis Clinical Site #99
Exelixis Clinical Site #135
Exelixis Clinical Site #18
Exelixis Clinical Site #73
Exelixis Clinical Site #132
Exelixis Clinical Site #32
Exelixis Clinical Site #74
Exelixis Clinical Site #37
Exelixis Clinical Site #137
Exelixis Clinical Site #134
Exelixis Clinical Site #120
Exelixis Clinical Site #53
Exelixis Clinical Site #10
Exelixis Clinical Site #105
Exelixis Clinical Site #88
Exelixis Clinical Site #126
Exelixis Clinical Site #42
Exelixis Clinical Site #25
Exelixis Clinical Site #161
Exelixis Clinical Site #69
Exelixis Clinical Site #156
Exelixis Clinical Site #47
Exelixis Clinical Site #92
Exelixis Clinical Site #9
Exelixis Clinical Site #130
Exelixis Clinical Site #116
Exelixis Clinical Site #82
Exelixis Clinical Site #154
Exelixis Clinical Site #131
Exelixis Clinical Site #16
Exelixis Clinical Site #52
Exelixis Clinical Site #61
Exelixis Clinical Site #95
Exelixis Clinical Site #39
Exelixis Clinical Site #128
Exelixis Clinical Site #5
Exelixis Clinical Site #111
Exelixis Clinical Site #72
Exelixis Clinical Site #20
Exelixis Clinical Site #138
Exelixis Clinical Site #79
Exelixis Clinical Site #163
Exelixis Clinical Site #94
Exelixis Clinical Site #41
Exelixis Clinical Site #157
Exelixis Clinical Site #55
Exelixis Clinical Site #27
Exelixis Clinical Site #158
Exelixis Clinical Site #107
Exelixis Clinical Site #19
Exelixis Clinical Site #96
Exelixis Clinical Site #64
Exelixis Clinical Site #87
Exelixis Clinical Site #117
Exelixis Clinical Site #139
Exelixis Clinical Site #153
Exelixis Clinical Site #119
Exelixis Clinical Site #104
Exelixis Clinical Site #142
Exelixis Clinical Site #45
Exelixis Clinical Site #90
Exelixis Clinical Site #59
Exelixis Clinical Site #115
Exelixis Clinical Site #81
Exelixis Clinical Site #35
Exelixis Clinical Site #40
Exelixis Clinical Site #129
Exelixis Clinical Site #143
Exelixis Clinical Site #113
Exelixis Clinical Site #38
Exelixis Clinical Site #28
Exelixis Clinical Site #150
Exelixis Clinical Site #22
Exelixis Clinical Site #26
Exelixis Clinical Site #54
Exelixis Clinical Site #118
Exelixis Clinical Site #57
Exelixis Clinical Site #84
Exelixis Clinical Site #108
Exelixis Clinical Site #58
Exelixis Clinical Site #133
Exelixis Clinical Site #106
Exelixis Clinical Site #98
Exelixis Clinical Site #144
Exelixis Clinical Site #12
Exelixis Clinical Site #46
Exelixis Clinical Site #34
Exelixis Clinical Site #114
Exelixis Clinical Site #65
Exelixis Clinical Site #162
Exelixis Clinical Site #44
Exelixis Clinical Site #121
Exelixis Clinical Site #151
Exelixis Clinical Site #159
Exelixis Clinical Site #124
Exelixis Clinical Site #141
Exelixis Clinical Site #30
Exelixis Clinical Site #68
Exelixis Clinical Site #43
Exelixis Clinical Site #77
Exelixis Clinical Site #86
Exelixis Clinical Site #15
Exelixis Clinical Site #102
Exelixis Clinical Site #24
Exelixis Clinical Site #2
Exelixis Clinical Site #7
Exelixis Clinical Site #164
Exelixis Clinical Site #67
Exelixis Clinical Site #80
Exelixis Clinical Site #122
Exelixis Clinical Site #50
Exelixis Clinical Site #6
Exelixis Clinical Site #3
Exelixis Clinical Site #63
Exelixis Clinical Site #140
Exelixis Clinical Site #21
Exelixis Clinical Site #17
Exelixis Clinical Site #100
Exelixis Clinical Site #70
Exelixis Clinical Site #155
Exelixis Clinical Site #71
Exelixis Clinical Site #103
Exelixis Clinical Site #49
Exelixis Clinical Site #89
Exelixis Clinical Site #66
Exelixis Clinical Site #23
Exelixis Clinical Site #146
Exelixis Clinical Site #110
Exelixis Clinical Site #62
Exelixis Clinical Site #8
Exelixis Clinical Site #125
Exelixis Clinical Site #11
Exelixis Clinical Site #36
Exelixis Clinical Site #14
Exelixis Clinical Site #83
Exelixis Clinical Site #56
Exelixis Clinical Site #145
Exelixis Clinical Site #78
Exelixis Clinical Site #93
Exelixis Clinical Site #97
Exelixis Clinical Site #152
Exelixis Clinical Site #109
Exelixis Clinical Site #123
Exelixis Clinical Site #148
Exelixis Clinical Site #149
Exelixis Clinical Site #51
Exelixis Clinical Site #75
Exelixis Clinical Site #147
Exelixis Clinical Site #33
Exelixis Clinical Site #101
Exelixis Clinical Site #76


title: Prospective Multicentre Observational French Cohort Study of Patients With Heart Failure and Central Sleep Apnoea Requiring Adaptive Servo-Ventilation (PaceWave, AutoSet CS) Treatment

acronym: FACE

summary: The purpose of FACE study is to provide in routine practice complementary long-term data on the mortality and morbidity of Chronic Heart Failure (CHF) patients with Central Sleep Apnea eligible for Adaptative Servo-Ventilation (ASV) treatment (PaceWave, AutoSet CS; ResMed).

ReferenceCitation: Tamisier R, Damy T, Davy JM, Verbraecken JA, Bailly S, Lavergne F, Palot A, Goutorbe F, Pépin JL, d'Ortho MP. Cohort profile: FACE, prospective follow-up of chronic heart failure patients with sleep-disordered breathing indicated for adaptive servo ventilation. BMJ Open. 2020 Jul 19;10(7):e038403. doi: 10.1136/bmjopen-2020-038403.

lead_sponsor: ResMed

location_facility: APHP - Pitié-Salpêtrière University Hospital

location_facility: Arnaud de Villeneuve University Hospital


title: Etude Resume (Retraitement Sunitinib Rein Metastatique)

acronym: RESUME

summary: Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.

time_perspective: Retrospective

lead_sponsor: Pfizer

location_facility: Centre Leon Berard, Service d'Oncologie Medicale

location_facility: Departement d'Oncologie Medicale-Institut de Cancerologie de la Loire

location_facility: Centre Oscar Lambret - Cancérologie Urologie Digestive

location_facility: Centre Rene Gauducheau - Service Oncologie Medicale

location_facility: Institut Paoli-Calmettes / Hôpital de jour


acronym: CUSTOMBONE

summary:
A Prospective, Multicenter Observational Study Evaluating the Long Term Safety in Terms of Explantation Rate and Number of Infections of the Custom-made Bioceramic Implant CustomBone™

The patients will be included as soon as they are implanted and follow-up for 2 years. It is observational so no specific exam is planned.

The explantation rate will be measured, that is to say the number of patients whose prosthesis will be removed (with or without any relationship with the implant or the procedure).

lead_sponsor: Integra LifeSciences Corporation

location_facility:
CH de la cote basque
CHU Lyon
Hôpital Ponchaillou
CHU la cavale blanche
Hopital Maison Blanche
CHU Hotel Dieu
CH Saint Etienne
CH Bretonneau
CHU Pasteur
CHU Angers
CHU Henri Mondor
Clinique du Tonkin
CHU Lariboisière
CHU La¨Pitié Salpêtrière
CHU Beaujon
CHU Hautepierre
CH Amiens
CHRU Roger Salengro


title: A Multicenter, Open, Randomized, Controlled Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA (L-asparaginase Encapsulated in Red Blood Cells, Eryaspase) Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Elderly Patients, Unfit for Intensive Chemotherapy

acronym: ENFORCE

summary: The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed with AML and unfit for intensive chemotherapy.

lead_sponsor: ERYtech Pharma

location_facility:
hopital de Perpignan
Institut de Cancérologie de la Loire
Hopital de Brabois
Hopital Morvan
Hôpital Haut-Lévèque
Groupe Hospitalier Sud
Hôpital JEAN MINJOZ
Hôpital Claude-Huriez
Centre Léon Bérard
CHRU de Nîmes
Hôtel Dieu - CHU de NANTES
Hopital Région d'Annecy
Hôpital l'Archet 1
CHU Estaing
Centre hospitalier Lyon Sud
Institut Paoli Calmettes
Hopital De Purpan CHU Toulouse
Chu D'Angers
Hôpital Saint Eloi
Centre Henri Becquerel
Hopital de Hautepierre


title: An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab

ReferenceCitation: Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. Eur J Cancer. 2017 Sep;82:230-236. doi: 10.1016/j.ejca.2017.05.009. Epub 2017 Jun 23.

location_facility: Centre Hospitalier Fleyriat; Oncologie/Hematologie

location_facility: HOP Prive Arras Les Bonnettes; Chimiotherapie

location_facility: Centre Eugene Marquis; Bureau D Etudes Cliniques

location_facility: Chp Saint Gregoire; Cancerologie Radiotherapie

location_facility: Centre Catherine de Sienne; Chimiotherapie

location_facility: Clinique De L Europe; Radiotherapie Chimiotherapie

location_facility: Hopital Belle Isle; Oncologie Hematologie

location_facility: HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune

location_facility: Institut Jean Godinot; Oncologie Medicale

location_facility: Clinique De La Sauvegarde; Chimiotherapie

location_facility: Centre Henri Becquerel; Oncologie Medicale

location_facility: Centre Hospitalier de La Cote Basque; Oncologie

location_facility: Centre Oscar Lambret; Unite de Recherche Clinique

location_facility: Hopital Prive Nord Parisien; Soins De Suite - Oncologie

location_facility: Institut Paoli Calmettes; Oncologie Medicale

location_facility: Ch Bretagne Sud Site Scorff; Oncologie Medicale

location_facility: Centre Georges Francois Leclerc; Oncologie 3

location_facility: Centre Hospitalier Universitaire de Poitiers

location_facility: Pole Sante Republique;Oncologie Hematologie

location_facility: Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE

location_facility: Polyclinique de la Cote Basque Sud; Oncologie

location_facility: Chi De Cornouaille; Oncologie Hospitalisation

location_facility: Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie

location_facility: CMCO De La Cote D Opale; Auberge De Jour

summary: This open-label, randomized, multicenter study will evaluate participant preference for subcutaneous (SC) versus intravenous (IV) trastuzumab (Herceptin) in participants with HER2-positive metastatic breast cancer responding to first-line treatment with IV trastuzumab for at least 3 years. Participants will be randomized to receive either 3 cycles (cycle length = 21 days) of trastuzumab SC followed by 3 cycles of trastuzumab IV or 3 cycles of trastuzumab IV followed by 3 cycles of trastuzumab SC. All participants will receive trastuzumab SC for Cycles 7 to 18. Anticipated time on study treatment is 1 year or until disease progression or inacceptable toxicity occurs, whichever comes first.


acronym: Néofirinox

intervention_type: Radiation

title: Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer

lead_sponsor: UNICANCER

ReferenceType: result

ReferenceCitation: Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.

ipd_sharing_description: Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.

location_facility: Centre Hospitalier de la Réunion - Site du GHSR

location_facility: Centre hospitalier Universitaire d'Amiens

location_facility: Institut de Cancérologie de Franche Comté

summary: National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with locally advanced rectal cancer.